The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
about
Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumorsA novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsExperimental approaches for the treatment of malignant gliomas.Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.Cellular and vaccine therapeutic approaches for gliomasThe Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.Immunotherapy of brain cancers: the past, the present, and future directions.CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival.Advances in translational research in neuro-oncologyHumoral immune response to keyhole limpet haemocyanin, the protein carrier in cancer vaccinesImmunotherapy for malignant gliomaGlioblastoma extracellular vesicles: reservoirs of potential biomarkers.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.The value of EGFRvIII as the target for glioma vaccines.Recent developments on immunotherapy for brain cancer.Antitumor cytotoxic T-cell response induced by a survivin peptide mimicTargeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.Frontiers in Suicide Gene Therapy of Cancer.Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical EffectsRecent advances and future of immunotherapy for glioblastoma.Suicide Gene Therapy for Cancer - Current Strategies.Therapeutic targeting of EGFR in malignant gliomas.Molecular diagnostics of gliomas: state of the art.Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?Gene therapy and virotherapy: novel therapeutic approaches for brain tumors.Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas.Evolution of care for patients with relapsed glioblastoma.Immunotherapy for the treatment of glioblastoma.Cancer immunoediting in malignant glioma.Molecular markers of glioma: an update on recent progress and perspectives.Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Erlotinib: early clinical development in brain cancer.Glioblastoma multiforme: State of the art and future therapeutics.Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigensCancer vaccine adjuvants--recent clinical progress and future perspectives.Current Studies of Immunotherapy on GlioblastomaVaccination strategies for neuro-oncology.Prospect of rindopepimut in the treatment of glioblastoma.
P2860
Q27010096-4EDBC5EF-38FD-427F-A9CE-724C12249ECCQ27011298-46D0B1C9-901E-47EA-BDED-D786DA92A02AQ33877450-C1230E36-9147-457C-A47F-35C4130CF4FBQ34127138-68F9B3AC-3F8F-4C26-B6F2-FD46AB9BD0B1Q34140756-571698CE-F4AC-4332-A84D-3A55D39D896CQ34243550-DBCC7AB9-0DF1-46CE-B7E2-89995E3FB3C8Q34553267-1332AE07-A413-4796-9A37-0E03ADC9F424Q34701587-33699960-68D1-4912-A4AF-70497018F4B2Q34721530-2FB38C1F-258F-4A13-B13F-4F5C247BC70BQ35029985-CC16589E-EE51-4020-9AAB-7C5D28DA393AQ35058011-21193B4D-F8B0-4476-88D4-01FF155732ABQ35114086-2E930739-5790-468D-B68D-25D56EB1198BQ35122209-208C9DB3-E931-40C3-A8D1-96ECB6886B64Q35285859-4F4A76ED-EF14-4514-86CD-EFE56377914FQ35627573-D322A63C-055C-4222-8E9A-FF17C7103BFEQ35992355-7E11A208-2186-43B8-9649-24DABC74846FQ36155913-678C32EB-8BF6-4BBB-822A-001E547D5D5AQ36297064-9C39B095-AB5F-4D6C-BA1D-05E45F2D0E08Q36534930-593D9DC7-1CBE-4989-85DE-D62E84532C4AQ36558234-1E7C3FD9-CEDF-4E97-B737-68430CA63319Q37132708-29F39657-FD9E-4CAA-91EA-DE08FADDE30EQ37239071-1811D5C2-19C5-4D91-B10C-5964D7AD8CCAQ37347017-A3AE3D29-C759-4013-9751-E0737C9FF123Q37690755-F6BEE4C0-6B0C-4DD9-9A06-41C77FE70FC9Q37780495-C7B0A01E-7BED-41A5-88B7-90B8AAD4BE0DQ37797464-4583DA43-1FA9-40FA-A1AB-948FFAAD52E9Q37804933-6DB218DD-6D5B-4453-A706-39ED3470BC78Q37869151-78225114-74D6-4FA0-91A4-E07448BB0029Q37952240-C2606B91-198B-4981-BF52-47A54F7E82F7Q37980026-0916B7AB-39A4-4F50-9CD7-811540C59D0DQ37986999-C65F5DE6-9720-4335-92B0-596E78D21614Q38050966-5632892B-DB1B-4986-9728-BC57DD13B509Q38203283-0A3B6FDE-A8CE-4BA1-BC07-CB618327E63EQ38212394-720B0892-32E9-459D-919D-627420F9AE5EQ38225874-7BA33F82-6B56-464B-B49F-05673DF92AF9Q38241483-7375ADE3-88B1-409E-9656-3928CA692BD9Q38260496-0C0D4D61-EA9D-4B15-86F7-859B7DF7BB66Q38262914-3A033C67-B060-403F-8DB3-059B91124C7BQ38620079-B7CC2DC4-3D59-4F6F-8122-225E27741197Q38748694-38B6F5C7-5C57-4A17-84C8-E304BAD0E0F1
P2860
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
@en
The PEPvIII-KLH
@nl
type
label
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
@en
The PEPvIII-KLH
@nl
prefLabel
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
@en
The PEPvIII-KLH
@nl
P2860
P1476
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
@en
P2093
Amy B Heimberger
P2860
P304
P356
10.1517/14712590903124346
P407
P50
P577
2009-08-01T00:00:00Z